Home | Life Sciences Intellectual Property Review
WEBOct 3, 2024 · In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results. 26 September 2024 Cameron Marshall, partner at Carpmaels, offers a behind-the-scenes snapshot of working a UPC case with tight deadlines and an ...
Latest News & Features | Life Sciences Intellectual Property Review
WEBPreventative IP for preventative pharma healthcare. The shift towards preventative pharmaceuticals could open new, and highly valuable, markets but it must be strengthened by patent rights, says Sam Andrews, senior paralegal at Powell Gilbert. 24 September 2024. Americas.
How to navigate patent term adjustment in China
WEB3 days ago · Same-date filing strategy. Rule 78.4 further excludes the eligibility of invention applications that take advantage of the utility model + invention ‘same day filing strategy’ (see our previous article).This refers to the situation where the applicant chooses to give up an earlier granted utility model patent to obtain the rights of the counterpart invention patent that was filed on the ...
Unified Patent Court | Life Sciences Intellectual Property Review
WEB12 December 2023 Hearing is latest in dispute between the biotech research firms | Multi-jurisdictional case concerns patents relating to the in-situ detection of analytes. 28 November 2023 UPC judge, EPO director and Regeneron counsel shed light on the court’s dynamics at London event | Life sciences sector emerging as a major player in the ...
Does the UPC offer a fresh take on patent validity?
WEBSep 5, 2024 · 20 August 2024 Preliminary injunction doesn't extend to Ireland because it has not ratified UPC Treaty | Case concerns dispute over patents covering continuous glucose monitoring devices used in the management of diabetes | Injunction in favour of the US market leader now applies to three markets rather than four.
2024 forecast: AI, patent eligibility and Fintiv
WEBJan 2, 2024 · NOTE - this can take up to 48hrs to be approved. Two Weeks Free Trial. For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at [email protected]. Americas. Americas. 2024 forecast: AI, patent eligibility and Fintiv.
CRISPR | Life Sciences Intellectual Property Review
WEB9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
EPO’s new examination guidelines: what you need to know
WEBApr 6, 2021 · A new edition of the European Patent Office (EPO) Guidelines for Examination came into force on March 1, 2021. Relevant to life sciences, this edition includes a new subsection detailing EPO practice with respect to the interpretation of terms relating to amino or nucleic acid sequences, as well as a new section on the examination of claims to antibodies.
‘This is a big problem’: The CRISPR controversy and the ‘mess’ at …
WEBSep 27, 2024 · A request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight.
UPC delivers first 'imminent infringement' decision in ...
WEBSep 9, 2024 · UPC clarifies that evidence must show that pre-launch preparations are complete for threat of imminent infringement to occur | Question remains over how the UPC will deal with the cumulative activities of several companies in a group | Court also broaches key cross-border question.